Literature DB >> 25065927

Clinical presentation and evaluation of neuroendocrine tumors of the lung.

Frank C Detterbeck1.   

Abstract

Neuroendocrine tumors of the lung encompass a wide spectrum. A carcinoid tumor is either a central smooth endobronchial tumor or a round, well-circumscribed, peripheral parenchymal lesion. Distinguishing typical carcinoid tumors from atypical carcinoid tumors is unreliable from a limited biopsy but can be based on age, presentation, and node enlargement. Large cell neuroendocrine cancer presents similarly to most non-small cell lung cancers. Small cell lung cancer has a characteristic presentation, with a rapid progression of symptoms, and a bulky central and/or mediastinal tumor. A diagnosis is achieved by limited biopsy and is usually reliable.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bronchopulmonary carcinoid tumors; Carcinoid tumors; Clinical presentation; Neuroendocrine tumors of the lung

Mesh:

Year:  2014        PMID: 25065927     DOI: 10.1016/j.thorsurg.2014.04.002

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  14 in total

1.  [Pulmonary carcinoid tumors].

Authors:  H Prosch
Journal:  Radiologe       Date:  2017-05       Impact factor: 0.635

2.  Do we really care about incidental lung nodules?-Review of atypical lung carcinoid and a proposal for systematic patient follow up.

Authors:  Henal Motiwala; Itisha Bansal; Pradeep Goyal; Olena Dorokhova; Yogesh Kumar; Thomas D Olsavsky; Albert DiMeo; Nishant Gupta
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 3.  [Resection concepts for early stage neuroendocrine tumors of the lungs and bronchi].

Authors:  T Ploenes; C Aigner
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

4.  Erroneous diagnosis of small cell lung cancer based on small biopsies with far-reaching consequences: case report of a typical carcinoid tumor.

Authors:  Ioannis Kyritsis; Bettina Krebs; Sandra Kampe; Dirk Theegarten; Clemens Aigner; Stefan Welter
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

Review 5.  Neuroendocrine Pulmonary Tumors of Low, Intermediate and High Grade: Anatomopathological Diagnosis-Prognostic and Predictive Factors.

Authors:  José Manuel Cameselle-Teijeiro; José Antonio Mato Mato; Ovidio Fernández Calvo; Jesús García Mata
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

6.  Role of wedge resection in bronchial carcinoid (BC) tumors: SEER database analysis.

Authors:  Mohamed Rahouma; Mohamed Kamel; Navneet Narula; Abu Nasar; Sebron Harrison; Benjamin Lee; Brendon M Stiles; Christopher Lau; Nasser K Altorki; Jeffrey L Port
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

7.  Clinicopathological, Oncogenic, and 18F-FDG PET/CT Features of Primary Pulmonary Carcinoid in Resection Specimens.

Authors:  Yun Chen; Yun Dong; Jingyun Shi; Long Zhao
Journal:  Contrast Media Mol Imaging       Date:  2022-06-15       Impact factor: 3.009

Review 8.  Advances on systemic treatment for lung neuroendocrine neoplasms.

Authors:  Nikolaos Tsoukalas; Panagiotis Baxevanos; Eleni Aravantinou-Fatorou; Maria Tolia; Michail Galanopoulos; Konstantinos Tsapakidis; George Kyrgias; Christos Toumpanakis; Gregory Kaltsas
Journal:  Ann Transl Med       Date:  2018-04

Review 9.  Lung neuroendocrine tumors: A systematic literature review (Review).

Authors:  Cornel Savu; Alexandru Melinte; Camelia Diaconu; Ovidiu Stiru; Florentina Gherghiceanu; Ștefan Dragoș Octavian Tudorica; Oana Clementina Dumitrașcu; Angelica Bratu; Irina Balescu; Nicolae Bacalbasa
Journal:  Exp Ther Med       Date:  2021-12-28       Impact factor: 2.447

10.  Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.

Authors:  Nicola Fazio; Roberto Buzzoni; Gianfranco Delle Fave; Margot E Tesselaar; Edward Wolin; Eric Van Cutsem; Paola Tomassetti; Jonathan Strosberg; Maurizio Voi; Lida Bubuteishvili-Pacaud; Antonia Ridolfi; Fabian Herbst; Jiri Tomasek; Simron Singh; Marianne Pavel; Matthew H Kulke; Juan W Valle; James C Yao
Journal:  Cancer Sci       Date:  2017-11-09       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.